We provide continuous financial coverage including stock performance, earnings expectations, and broader economic indicators.
As of April 6, 2026, Replimune Group Inc. (REPL) trades at $8.59 per share, posting a 2.14% gain on the day. This analysis examines recent trading context, key technical levels, and potential near-term scenarios for the clinical-stage biotechnology firm, which focuses on developing oncolytic immunotherapies for cancer treatment. Recent price action for REPL has been range-bound, with traders closely monitoring key support and resistance marks for signs of a potential shift in short-term momentum
Will Replimune Group (REPL) Stock Outperform Peers | Price at $8.59, Up 2.14% - Combination Correction
REPL - Stock Analysis
4483 Comments
827 Likes
1
Ansor
Expert Member
2 hours ago
{协议答案}
👍 152
Reply
2
Alexica
Senior Contributor
5 hours ago
{协议答案}
👍 257
Reply
3
Alexzandar
Power User
1 day ago
{协议答案}
👍 122
Reply
4
Joequan
Registered User
1 day ago
{协议答案}
👍 56
Reply
5
Dierdra
Returning User
2 days ago
{协议答案}
👍 276
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.